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Abstract
Breast cancer is the second leading cause of cancer mortality among women. Given its important
role in DNA methylation and synthesis, one-carbon metabolism may affect breast cancer mortality.
We utilized a population-based cohort of 1,508 women with breast cancer to investigate possible
associations of dietary intake of B vitamins prior to diagnosis as well as 9 polymorphisms of one-
carbon metabolizing genes and subsequent survival. Women newly diagnosed with a first primary
breast cancer in 1996-1997 were followed for vital status for an average of 5.6 years. Kaplan-Meier
survival and Cox proportional hazard regression analyses were used to evaluate the association
between dietary intakes of B vitamins (1479 cases), genotypes (∼1065 cases) and all-cause as well
as breast cancer-specific mortality. We found that higher dietary intake of vitamin B1 and B3 was
associated with improved survival during the follow-up period (p for trend = 0.01 and 0.04,
respectively). Compared to the major genotype, the MTHFR 677 T allele carriers have reduced all-
cause mortality and breast cancer-specific mortality in a dominant model [HR and 95% CI: 0.69
(0.49-0.98) and 0.58 (0.38-0.89), respectively). The BHMT 742 A allele was also associated with
reduced all-cause mortality [HR 0.70(0.50-1.00)]. ER/PR status modified the association between
the MTHFR C677T polymorphism and survival (p=0.05). The survival associations with one-carbon
polymorphisms did not differ with the use of chemotherapy, although study power was limited for
examining such effect modification. Our results indicate that one-carbon metabolism may be an
important pathway that could be targeted to improve breast cancer survival.
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The 5-year survival rate for breast cancer among US women has increased from 75% during
1974-76 to 85% during 1989-95 (1,2). Despite such marked improvement, breast cancer
remains the leading cause of cancer mortality among women 20 – 59 years of age and the
second leading cause of cancer mortality among all women (1). Disease-free survival after
breast cancer treatment may be partially predicted by tumor size, hormone receptor status and
other clinical and pathological factors (3-7). Although a number of lifestyle and host factors
have been inconsistently or infrequently reported to impact disease-free or overall survival,
only a few have been firmly established to adversely affect survival, including age, race and
obesity (8-10); few of these are factors that a patient can actively modify or that can help
clinicians to tailor an effective treatment.
One-carbon metabolism may influence breast cancer mortality because of the critical role it
plays in both DNA methylation and DNA synthesis (Figure 1). An abnormal methylation
profile such as promoter-CpG island hypermethylation is a common molecular defect in cancer
cells (11,12). Estrogen receptor (ER) and progesterone receptor (PR) status have been used
widely as a prognostics markers as well as indicators for tailoring breast cancer treatment
(endocrine- vs. chemotherapy)(13). Loss of function of these genes has been shown to predict
poor prognosis of breast cancer (14). Promoter hypermethylation has been implicated as the
underlying mechanism for silencing of these receptors (12,15-17). Both dietary factors, such
as folate and related B vitamins, and genetic variations of one-carbon metabolizing genes may
modify the methylation profile of these prognostic genes, thus influencing breast cancer
survival.
Another reason one-carbon metabolism may influence breast cancer survival is that it is the
direct target for several widely used anti-cancer drugs. Combination chemotherapy with
cyclophosphamide, methotrexate, and 5-Fluorouracil (CMF) has been the treatment of choice
for the majority of patients with stage II, node-negative breast cancer, as clinical trials have
demonstrated its efficacy and long-term safety (18). 5-fluorouracil targets the enzyme
thymidylate synthase (TYMS) while methotrexate targets dihydrofolate reductase (DHFR),
both involved in one-carbon metabolism (Figure 1). These drugs block DNA synthesis and
ultimately cell replication. Genetic variations of these enzymes may have functional
consequences and ultimately impact the efficacy of the CMF treatment modality.
In humans, folate plays the fundamental role of providing methyl groups for intracellular
methylation reactions and de novo deoxynucleoside synthesis. Folate deficiency is associated
with genomic instability and could lead to abnormal DNA methylation status (19). Recently,
studies on colorectal cancer suggested that folate may play a dual role in tumor progression
(20,21). While folate is in general anti-neoplastic before the tumor foci are established, it may
enhance tumor proliferation after the tumor is established. Thus the effect of one-carbon
metabolism on breast cancer survival may be complicated. Utilizing the population-based data
from the Long Island Breast Cancer Study Project (LIBCSP), we investigated the associations
of dietary intakes of B vitamins prior to diagnosis as well as functional polymorphisms in one-
carbon metabolism and breast cancer survival.
METHODS
Study population
We utilized data from the follow-up study of the LIBCSP, a population-based study that
includes women newly diagnosed with a first primary breast cancer who participated in the
original case-control study (22) and were subsequently re-interviewed about five years later
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and followed for vital status (23). The study protocol was approved by the Institutional Review
Boards of the collaborating institutions.
Women considered eligible for the follow-up study included all case participants of the parent
case-control study, which includes 1,508 women with a first primary in situ or invasive breast
cancer who were newly diagnosed between August 1, 1996 and July 31, 1997, and were
residents of Nassau or Suffolk counties, Long Island, NY, at the time of diagnosis. Cases were
identified through review of pathology/cytology records of 33 collaborating institutions and
were contacted by letter and telephone after obtaining physician permission.
As previously reported (22), at the time of the first primary breast cancer diagnosis, the mean
age was 58.8 years (range: 25.1-98.1); 94% were white, 4% were African American, and 2%
were other; 235 (15.6%) had carcinoma in situ and 1273 (84.4%) had invasive tumor; 472
(31.3%) women were pre-menopausal and 1006 (66.7%) were post-menopausal; and 583
(58.9%) were ER+/PR+; 143 (14.4%) were ER+/PR−; 52 (5.3%) were ER−/PR+; and 212
(21.4%) were ER−/PR−.
Exposure assessment
Exposure data was obtained as part of the 1) case-control (baseline) interview; 2) follow-up
interview; and 3) medical record abstraction, as described below. For our analyses, dietary
intake data and most of the potential confounders and effect modifiers were derived from the
baseline interview. Complete course of treatment for the primary breast cancer was obtained
during the follow-up interview and through medical record abstraction.
Case-control data—The baseline questionnaire was administered by a trained interviewer
approximately 3 months after diagnosis (average time was 96 days) and elicited information
on reproductive/menstrual history, cigarette smoking, alcohol, body size, physical activity, and
medical history (http://www.epi.grants.cancer.gov/LIBCSP/projects/Questionnaire.html).
Dietary intake in the year prior to the interview (which primarily reflects pre-diagnostic intake)
was assessed using a self-administered modified Block Food Frequency Questionnaire (FFQ)
that was completed at the time of the baseline interview (24). The frequency and portion sizes
data were translated to daily intakes of nutrients from both dietary and supplement sources
using the National Cancer Institute's DietSys version 3. Habitual use of multivitamin
supplements was also obtained from the FFQ. The questions included multivitamin use over
the past 10–15 years before the interview, type of multivitamin, and dosage. Details have been
described previously (24-26). Total folate was calculated by using the estimated dietary folate
equivalent (DFE) conversion factor of 1.7 for folic acid from supplement (27,28): total folate
= dietary folate + 1.7 × supplement folate. In this study, we examined the B vitamins (folate,
B1, B2, B3, B6, and B12) and two cofactors involved in methyl transfer in the one-carbon
metabolism pathway, namely, methionine and betaine. Spearman coefficients ranged from a
low of 0.41 between total folate and vitamin B3 to a high of 0.90 between dietary folate and
vitamin B1 (29). Energy intake was also estimated using data collected from the FFQ. The
dietary intake information was available for 1479 cases in our analysis.
Follow-up data—In 2002-2004, case participants, or their proxy (close relative or friend)
were re-contacted first by mail, and then by telephone, to invite them to participate in the
follow-up study (23,30). Follow-up data used in this study were the information for tumor
characteristics (tumor size and nodal status) and treatment information. Of the 1098 case
women for whom we have data from the follow-up questionnaire: 784 (71.4%) completed the
full interview themselves; 165 (15.0%) respondents completed the critical interview which was
an abbreviated questionnaire that focused on collecting treatment data only; and 84 (7.7%)
proxy interviews were conducted. Among the 1022 case women who provided information on
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chemotherapy at the time of the follow-up interview, 423 (41.4%) reported receiving
chemotherapy as part of their first course of treatment for their primary breast cancer diagnosis.
Medical record data—For cases who signed medical record release forms, medical records
were abstracted twice: at baseline (as part of the case-control study) and again during the
follow-up study. At baseline, information was obtained on disease stage (in situ/invasive),
tumor size, ER/PR status (assessed by immunohistochemistry, n = 990), and initial course of
treatment for their breast cancer. Over three quarters of the baseline case interviews occurred
prior to the initiation of chemotherapy (22). Additional treatment information was obtained by
re-abstracting medical records as part of the follow-up study. Among the subset of women for
whom we had complete course of treatment data from the medical record (n = 499), we
compared their self-reported responses at the follow-up interview with the medical record data
using the kappa coefficient; concordance between the two sources was high (kappa = 0.97 for
radiation therapy, 0.96 for chemotherapy, and 0.92 for hormone therapy)(23).
Blood sample collection and genotyping
Blood samples were collected from 73% of the 1508 cases at the time of the baseline interview
by trained field staff (22). DNA was isolated from blood specimens using the methods
previously described (25); DNA was available from 1065 individuals for genotyping. Using
methods described elsewhere (29,31), genotyping was conducted on 9 polymorphisms in the
one-carbon metabolism pathway, namely: MTHFR C677T (rs1801133) and A1298C
(rs1801131); TYMS 5′-UTR tandem repeat; DHFR 19bp deletion; MTR A2756 (rs1805087);
MTRR A66G (rs1801394); BHMT G742A (rs3733890); RFC1 A80G (rs1051266); and cSHMT
C1420T (rs1979277). The mean call rate was 96%; the main reason for missing genotypes was
insufficient DNA. About 10% of the study population samples were randomly duplicated as
quality control samples; the concordance rate was >98% for all polymorphisms in this study.
All laboratory personnel were blinded to the outcome status of the breast cancer cases as well
as quality control status of the specimens. Characteristics were comparable between cases with
blood and those with genotype information available.
Study outcome
The National Death Index was used to ascertain all-cause and breast cancer-specific mortality.
Among the 1508 women diagnosed with breast cancer in 1996–1997, 198 (13.1%) deaths
occurred by December 31, 2002. The mean follow up time was 5.6 years (range: 0.2-7.4).
Based on International Classification of Diseases (ICD) codes 174.9 and C-50.9 listed as a
primary or secondary code on the death certificate, 124 (62.6%) of these 198 deaths were due
to breast cancer. When restricted to the cohort from which DNA was available for genotype
analysis (n=1065), a total of 131 (12.3%) deaths were observed; 84 (64.1%) of these were due
to breast cancer.
Statistical Analysis
The Kaplan-Meier and the log-rank test were used to examine the crude association between
dietary intake or genotypes and survival (32). The Cox proportional hazard regression (32) was
used to estimate the hazard ratio (HR) and 95% confidence interval (CI) for all-cause and breast
cancer-specific mortality, with adjustments made for age at diagnosis (continuous) and energy
intake (quintiles). Nutrient intakes in the year prior to the interview were categorized based on
the distributions observed among all cases regardless of outcome status; results based on tertiles
are shown. Tests of trend were conducted by coding the variables ordinarily in the model. To
increase statistical power, heterozygous and variant homozygous genotypes were combined as
a single risk group.
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Confounding was evaluated using the methods described by Rothman and Greenland (33)
starting with a full multivariate model and using backward elimination. Factors considered as
potential confounders included: menopausal status (pre-/post-menopausal), family history of
breast cancer in a first-degree relative, cancer type (in situ/invasive), active/passive cigarette
smoking, body mass index (BMI) at diagnosis, average lifetime alcohol intake (g/day),
education, income, tumor size, and radiation treatment and chemotherapy undergone for the
original breast cancer diagnosis. If eliminating a covariate from the full Cox regression model
changed the effect estimate by 10% or more, the covariate was considered a confounder and
kept in the model (33). Otherwise that covariate was dropped from the multivariate model.
None of the covariates tested met such criterion, thus, only results adjusted for age and energy
intake are presented.
Effect modification on the multiplicative scale was evaluated using the log likelihood ratio test
to compare Cox models with and without the interaction term as a cross-product term of
genotype and effect modifier. Factors considered as potential effect modifiers of the genotype-
mortality association include: menopausal status (pre-/post-menopausal), cancer type (in
situ/invasive), ER/PR status [cases were categorized to two groups: ER and PR both positive
(ER+/PR+) vs. all others (ER+/PR−, ER−/PR+, ER−/PR−) and when the latter receptor types
were analyzed individually, their respective HRs were similar] and chemotherapy. P values
for the interaction were evaluated for the potential modification on gene effect by factors
examined.
Unconditional logistic regression was used to explore the relationship of one-carbon genotype
and hormone receptor (ER/PR) status. Genotypes were used as exploratory variables in the
model. ER/PR status (either both positive vs. all others) was treated as outcome in the logistic
regression model and the odds ratio (OR) and 95% CI were estimated by modeling the
probability of the case tumor being ER/PR positive.
All statistical analyses were performed using SAS statistical software version 9.1(SAS
Institute, Cary, NC).
RESULTS
The associations between dietary intake of B vitamins in the year prior to the baseline interview
and subsequent all-cause as well as breast cancer specific mortality are summarized in Table
1. Intake of vitamin B1 and B3 were inversely associated with all-cause mortality in this
population-based cohort of women with breast cancer. Compared to the low intake group, cases
in the high intake group had a 46% (HR and 95% CI: 0.54; 0.34-0.88) and 39% (HR and 95%
CI: 0.61; 0.38-0.98) lower risk of death for B1 and B3, respectively. Trend tests for the
associations were significant (p for trend =0.01 for B1 and 0.04 for B3). Although beneficial
effects were observed for other one-carbon related B vitamins (except for B12), where all the
HRs were less than one, the reductions were not statistically significant. No association was
observed for intakes of methionine or betaine and all-cause mortality. When we examined the
association with breast cancer-specific mortality, similar HRs were observed (Table 1);
however, the association for vitamin B3 did not reach significance (p for trend =0.09).
Table 2 summarizes the association between one-carbon polymorphisms and all-cause as well
as breast cancer-specific mortality. The variant alleles of two polymorphisms, MTHFR
C677T and BHMT G742A, were significantly associated with better survival. The
MTHFR677 T allele carriers had 31% lower risk of death than patients with the MTHFR677
CC genotype (HR and 95% CI: 0.69; 0.49-0.98). BHMT 742 A allele carriers had 30% lower
risk of death than those with the BHMT GG genotype (HR and 95% CI: 0.70; 0.50-1.00). Two
other single nucleotide polymorphisms (SNPs), MTR2756 G and cSHMT1420 T alleles were
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associated with better survival with borderline significance. When we examined breast cancer-
specific mortality, similar results were observed (Table 2); however, the association with
BHMT did not reach statistical significance (p=0.11).
To explore whether two SNPs, MTHFR C677T and BHMT G742A, influence breast cancer
survival via the hormone receptor (ER/PR) status of the tumor, we examined the associations
between genotypes and ER/PR status (Table 3). Tumors of cases with the MTHFR677 TT
genotype had an ∼60% higher chance to be ER/PR positive compared to tumors of individuals
with the CC genotype. Tumors of the T allele carriers had an ∼28% higher chance to be ER/
PR positive. There was no relationship between the BHMT polymorphism and ER/PR status
in this population. Although no main effects on mortality were observed for other 7
polymorphisms investigated in the study, we also examined the associations between
genotypes and ER/PR status but no association was found (data not shown).
We also examined whether the polymorphism-survival relationship differed by hormone
receptor (ER/PR) status. Effect modification by ER/PR status was observed with respect to the
MTHFR C677T polymorphism and all-cause mortality (p for interaction = 0.05). The T allele
was associated with better survival with borderline significant in all-cause mortality only
among the grouped cases with ER+/PR−, ER-/PR+ and ER−/PR− status (HR: 0.61; 0.36-1.01).
The associations between other 8 polymorphisms and survival did not differ with respect to
hormone receptor status (data not shown).
To explore the potential modifying effect of one-carbon gene polymorphisms on chemotherapy
response in relation to breast cancer survival, we stratified the cases by whether they received
chemotherapy or not. About 800 cases with both genotype and chemotherapy treatment
information were include in this analysis. Associations of one-carbon metabolism
polymorphisms and overall survival did not differ by chemotherapy status (data not shown).
DISCUSSION
Utilizing data from a population-based cohort of breast cancer cases, we found inverse
associations between several micronutrients and genotypes in the one-carbon metabolism and
all-cause mortality. To the best of our knowledge, our study is the first to systematically
evaluate pre-diagnostic intake of B vitamins involved in one-carbon metabolism pathway in
relation to breast cancer survival. This study is based on a strong biological rationale because
one-carbon metabolism not only involves in regulation of prognosis-predictive genes in breast
cancer but also is the major target for treatment of the disease (Figure 1). Considering the high
prevalence of these polymorphisms in the general population, results from the study can help
us to identify factors that may influence disease outcomes.
B vitamins (B1, thiamin; B2, riboflavin; B3, niacin; B6, pyridoxine; B9, folate; B12, cobalamin)
play important roles in cell metabolism, and some of them are cofactors involved in the one-
carbon pathway. In a previous report (29), we found that increased dietary intakes of B vitamins
were associated with reduced risk of developing breast cancer. Herein, we reported a beneficial
effect of B vitamins, B1 and B3 in particular, on survival in the same population of breast cancer
cases. These findings imply that a healthy diet reduces a woman's risk of developing breast
cancer, but should a breast cancer occur, the tumor would also display characteristics associated
with a more favorable prognosis.
In this study, we found two genetic polymorphisms, MTHFR C677T and BHMT G742A, were
inversely associated with all-cause mortality. MTHFR catalyzes an irreversible reaction and it
is the rate-limiting step in folate metabolism. Changes in MTHFR activity may tilt the balance
of one-carbon metabolism in favor of DNA synthesis at the expense of methyl supply (i.e. S-
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Adenosylmethionine) for methylation reactions. The C677T polymorphism of MTHFR results
in an alanine to valine substitution and has been correlated with enzyme thermolability and
reduced enzyme activity (34). Lower MTHFR activity has been shown to decrease DNA
methylation in animal experiments (35). DNA methylation has been implicated in the silencing
of ER, a prognosis-predictive gene (12,15-17). Consistent with this reasoning, the TT genotype
was associated with ER+/PR+ tumors in our study population (Table 3) leading to improved
survival. This finding is based on a small sample size, and replication is warranted.
Although not directly involved in folate metabolism, BHMT is involved in the metabolism of
homocysteine. BHMT may play a critical role in the remethylation of homocysteine when the
folate-dependent pathway is compromised by either genetic or dietary factors (36). The BHMT
G742A polymorphism was associated with overall survival in our study population; it is
unknown whether homocysteine level correlates with breast cancer prognosis in our study
population.
Many studies have been conducted to examine the effects of one-carbon metabolism
polymorphisms on breast cancer risk, but reports of effects on subsequent survival are relatively
sparse. There are two other studies that examined the effect of MTHFR genotypes on breast
cancer survival. Results from the Shanghai Breast Cancer study showed that MTHFR
genotypes were not associated with all-cause mortality, but the 677TT genotype was associated
with poor survival among those with late stage disease (37). In our study, we observed a
beneficial effect of the MTHFR677 T allele on all-cause mortality. Difference among these
reports could be due to the difference in study populations, given that our population is
overwhelmingly Caucasian, whereas the Shanghai Breast Cancer Study is restricted to Chinese
women. Factors that may influence the MTHFR-survival relationship, such as treatment
modality, may also be different in these two populations. Results from a small cohort reported
by Martin et al. showed that MTHFR1298 C allele was associated with worse survival
compared to the AA genotype; furthermore, this effect was stronger in ER- patients (38). This
latter study is based on a cohort containing a mixture of Caucasian and African-American
women and the sample size was relatively small (∼250).
We did not observe any survival differences by genotype stratified by chemotherapy. Although
our sample size is much larger than previous studies, statistical power is still limited in stratified
analyses. In addition, because the LIBCSP is a population-based study, the breast cancer
patients were treated in multiple institutions with non-standardized protocols. The majority of
women in our study received adjuvant chemotherapy as part of their regular treatment for breast
cancer. Specific information such as chemotherapy dose and duration were not available for
all our study subjects, which limited our ability to examine the potential interaction between
one-carbon metabolism and chemotherapy. Investigation of such relationships in the context
of a larger population of breast cancer patients with more complete information on treatment
modality is warranted, since it is plausible that these factors could potentially be used to tailor
treatment and ultimately improve survival.
In our study, we did not find any substantial differences in terms of associations of one-carbon
metabolism with all-cause mortality and breast cancer specific mortality. Vitamin B3 intake
and BHMT (G742A) polymorphism were associated with all-cause mortality but did not reach
statistical significance for breast cancer specific mortality. Given the point estimates are
similar, the wide confidence interval could be a result of limited study outcome (∼130 death).
Results on breast cancer-specific mortality may help us better understand the role of one-carbon
metabolism in breast cancer progression and to develop more efficient treatment for this
disease. Accurate assessment on cause of death is crucial in this type of investigation (39-41).
The reliability of the cause of death listed on the death certificate, particularly when looking
at a specific cancer site may be questionable, e.g. sometimes a metastatic site may be recorded
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as the cause of death (42,43). Thus, our findings based on all-cause mortality may be more
valid. In addition, estimation of overall survival (with death as the end point regardless of the
specific cause) is of public health significance and provides us with better power for detecting
associations (44).
We utilized the dietary information collected at the baseline interview, which reflects intake
patterns one year prior to the interview including the months just prior to and at diagnosis.
Recall of this information was ascertained prior to the study outcome (i.e. death), thus any
possible misclassification is likely to be non-differential. However, it is possible that patients
change their lifestyle after a diagnosis of cancer (45,46). Consequently, our results should be
interpreted with caution. Studies have indicated that after breast cancer diagnosis, women are
motivated to change their diet, but this is observed primarily in younger women (47,48); our
study population, on the other hand, is primarily composed of postmenopausal women.
Interestingly, a substantial percentage (50%) of cancer survivors has been reported to continue
to engage in health-risk behaviors (45). As discussed in a recent review, supplement use among
breast cancer patients is high and frequently increases after diagnosis (49). We were unable to
identify studies that specifically address the issue of whether breast cancer survivors change
their dietary intake of foods containing B vitamins after diagnosis. If women in our study
continued to follow their pre-diagnostic diets after their breast cancer diagnosis, then the
implications of our results are that women in the general population should be encouraged to
consume more B vitamins.
One potential issue to consider in interpreting our results is whether our analyses should have
considered the potential confounding effects of tumor stage (or its surrogates tumor size and
first course of treatment). However, because tumor stage is more likely a causal intermediate
(e.g. the biological link between the exposure with the outcome), it would be epidemiologically
inappropriate to include tumor stage in the model. However, in sub-analyses we did consider
the potential confounding effects of tumor size and first course of treatment (as surrogates for
tumor stage, which was not reliably recorded on the medical record for all cases), and found
that our results remain unchanged.
A potential limitation of our study is that we focused solely on the dominant model in our
genetic association analyses. Consideration of other models would be of interest, but because
our study power was constrained by the number of deaths (about 130) in our cohort of breast
cancer cases, the results would be unstable and perhaps misleading. Another limitation of our
study is its limited power for testing potential gene-gene and gene-diet interactions. Thus we
did not investigate these interactions in our analysis.
In summary, results from our population-based study suggest that in addition to its role in breast
cancer etiology, one-carbon metabolism may be an important pathway that can be targeted to
improve breast cancer survival among women with breast cancer.
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Schematic illustration of one-carbon metabolism pathway. Key genes involved in one-carbon
metabolism include methylenetetrahydrofolate reductase (MTHFR), thymidylate synthase
(TYMS), methionine synthase (MTR), methionine synthase reductase (MTRR), cytosol serine
hydroxymethyltransferase (cSHMT), dihydrofolate reductase (DHFR), and betaine-
homocysteine methyltransferase (BHMT). Reduced folate carrier (RFC1) and human folate
receptor (hFR) transport the dietary polyglutamyl folate (the predominant form of folate in
diet) in intestinal absorption. B vitamins are co-factors of one-carbon enzymes as shown.
Chemotherapy drugs 5-fluorouracil (5-FU) targets TYMS and methotrexate targets DHFR to
block DNA synthesis. Hcy, homocysteine; SAM, S-adenosylmethionine; SAH,
adenosylhomocysteine; THF, tetrahydrofolate; DHF, dihydrofolate; dUMP, deoxyuridine
monophosphate; dUTP, deoxythymidine monophosphate.
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